Healthtech startup Temple, founded by Zomato CEO Deepinder Goyal, has acquired London-based Longevous, an evidence-based longevity medicine practice. The acquisition comes as Temple prepares to launch its wearable health technology platform and expand its longevity-focused healthcare ecosystem.
The acquisition is aimed at enhancing Temple’s scientific and clinical capabilities, with Longevous founders Dr Robert Mohr and Dr. Avi Roy joining the company in full-time leadership roles. Announcing the development, Goyal said the acquisition will bring both founders and their team into Temple as the company continues to build its longevity-focused health ecosystem.
As part of the transition, Dr. Robert Mohr will take on the role of Chief Medical Officer at Temple. Mohr is a board-certified physician with nearly two decades of clinical experience. Over the course of his career, he has worked across emergency medicine, preventive healthcare, precision medicine, and longevity-focused clinical practice. His experience will therefore strengthen Temple’s clinical capabilities as the company develops its health technology platform.
Meanwhile, Dr. Avi Roy will join as Head of Science. Roy, an Oxford-trained biomedical scientist, has developed expertise at the intersection of longevity research and healthcare innovation. He is also known for co-founding Founders Health and UDA and previously served as a research fellow at the University of Oxford’s Centre for the Advancement of Sustainable Medical Innovation. His research background will support Temple as it advances its scientific framework and longevity-focused technology.
According to Goyal, the relationship began following a meeting with Mohr and Roy at a dinner event in London a few months ago. The initial discussions focused on longevity science and eventually prompted Mohr and Roy to test Temple’s technology. Subsequently, the pair became more closely involved with the company’s research initiatives.
Over a two-month period, Mohr and Roy used Temple’s wearable device as part of their daily routines. During this period, they also collaborated with Temple’s science team to evaluate its proprietary ‘Entropy’ metric and the physiological data generated by the device. They also reviewed aspects of the company’s scientific framework, challenged existing assumptions, and provided feedback on research papers before submission.
The collaboration eventually led to the acquisition, bringing Longevous’ expertise into Temple while allowing the practice to retain its existing identity. While becoming part of Temple, Longevous will continue operating under its existing brand structure, with Mohr and Roy maintaining support for its current client base.
Temple is focused on developing wearable technology designed to track physiological signals and longevity-related health indicators. The startup has designed its wearable device to sit near the temple region and incorporated a proprietary measurement called Entropy. According to the company, the metric helps assess the body’s real-time energy expenditure.
Temple expects to launch its wearable product within the next year. Meanwhile, the company is placing greater emphasis on scientific validation as it prepares for the product launch. Earlier, Goyal indicated that the health-related claims associated with the device would receive support from peer-reviewed scientific studies.
The acquisition therefore gives Temple additional clinical and scientific expertise as it moves closer to launching its wearable technology. By bringing Mohr and Roy into leadership positions, the company can combine longevity medicine, biomedical research, and wearable technology within a broader health ecosystem. At the same time, Longevous will continue serving its existing clients under its current brand, creating continuity during the transition.
Temple’s move also highlights the growing interest in longevity medicine and technology-driven healthcare. As wearable devices generate increasingly detailed physiological data, companies are seeking stronger scientific frameworks to interpret that information. Consequently, Temple’s collaboration with longevity specialists could play an important role in shaping its approach to preventive healthcare, physiological monitoring, and evidence-based longevity.
